Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Browsing Tag

multiple sclerosis

48 posts
RRoche
What Could Roche Holding (SWX:ROP) Gain From FDA Priority Review In MS?
Read More

What Could Roche Holding (SWX:ROP) Gain From FDA Priority Review In MS?

  • 2026-10-19
Roche Holding (SWX:ROP) received FDA acceptance of its New Drug Application for fenebrutinib in multiple sclerosis under priority…
RRoche
Roche’s Fenebrutinib Receives FDA Priority Review for Relapsing and Primary Progressive Multiple Sclerosis
Read More

Roche’s Fenebrutinib Receives FDA Priority Review for Relapsing and Primary Progressive Multiple Sclerosis

  • 2026-09-30
Researcher with pipette ©National Institutes of Health The FDA has accepted fenebrutinib for priority review across two forms…
BBern
More than 1,200 cyclists ride through New Bern for annual Bike MS event
Read More

More than 1,200 cyclists ride through New Bern for annual Bike MS event

  • 2026-09-19
The above video is our WITN+ livestream and may not reflect the content in this story. NEW BERN,…
NNovartis
Novartis Stock Prices Rise After Positive Multiple Sclerosis Drug Trial Results
Read More

Novartis Stock Prices Rise After Positive Multiple Sclerosis Drug Trial Results

  • 2026-09-14
Novartis NOVN -0.09%decrease; down pointing triangle shares rose after the drugmaker reported positive results from two late-stage trials…
NNovartis
StockWatch: Novartis Loses More than Market Value After Phase III Failure
Read More

StockWatch: Novartis Loses More than Market Value After Phase III Failure

  • 2026-09-14
A Novartis researcher at work. Novartis saw some of its top investors publicly express dissatisfaction with its direction…
NNovartis
Could Remibrutinib Become the Next $9 Billion Drug for Novartis?
Read More

Could Remibrutinib Become the Next $9 Billion Drug for Novartis?

  • 2026-09-11
Novartis AG (NYSE:NVS) has reported the first major success from three closely watched pipeline programs expected to produce…
RRoche
Roche gets Phase 3 trial waiver for higher dose of multiple sclerosis drug | Industry News
Read More

Roche gets Phase 3 trial waiver for higher dose of multiple sclerosis drug | Industry News

  • 2026-09-04
CDSCO expert panel grants waiver for 920 mg Ocrelizumab, subject to Roche conducting a Phase 4 clinical trial…
RRoche
Business Standard
Read More

Roche gets Phase 3 trial waiver for higher dose of multiple sclerosis drug | Industry News

  • 2026-09-04
Global pharma major Roche has been given a Phase 3 trial waiver for a higher dosage form of…
NNovartis
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
Read More

Novartis’ Remibrutinib Delivers Positive Results in Late-Stage MS Studies

  • 2026-09-02
Novartis NVS announced positive top-line results from the late-stage REMODEL-1/-2 studies on remibrutinib in relapsing multiple sclerosis (RMS).…
NNovartis
A computer rendering of a CAR-T cell attacking a Hodgkin lymphoma cell.
Read More

Will Patient Deaths Derail the CAR-T Train in Autoimmune Disease?

  • 2026-09-02
Two Big Pharma companies have reportedly paused their ongoing trials of chimeric antigen receptor (CAR) T-cell therapies in…
NNovartis
Novartis' Remibrutinib Shows Superior Efficacy in MS Trials, Outshining Older Treatment, ETPharma
Read More

Novartis’ Remibrutinib Shows Superior Efficacy in MS Trials, Outshining Older Treatment, ETPharma

  • 2026-09-02
London: Swiss drugmaker Novartis said on Tuesday its oral drug remibrutinib outperformed an older treatment in reducing relapses…
NNovartis
health-novartis - 1
Read More

Novartis pauses 8 cell therapy trials after three die due to severe immune reaction

  • 2026-09-02
Following the death of three patients who were part of an experimental cell therapy called rap-cel, Novartis decided…
Switzerland
www.europesays.com